Moleculin Biotech Files for Public Offering of Stock & Warrants

Moleculin Biotech, Inc. filed an S-1/A for a public offering of up to 4,566,210 shares of common stock, up to 4,566,210 pre-funded warrants, and up to 13,698,630 common warrants. The assumed combined public offering price is $2.19 per share and common warrants, aiming to raise approximately $9.1 million in net proceeds. The company intends to use these funds to advance the clinical development of Annamycin, including the ongoing Phase 2/3 MIRACLE trial for relapsed/refractory AML, and for general working capital. The offering is on a "reasonable best efforts" basis with no guarantee of a minimum amount of proceeds, and it carries significant dilution risk for existing shareholders.